| Name | Title | Contact Details |
|---|
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we`re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Vit Best Nutrition is a fully integrated contract manufacturer for the Nutritional Supplement Industry, offering a wide range of production capabilities for tablets, capsules, and powders.
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.